Skip to content
DataLookout
Menu

NCT07909122

Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer

StatusNot Yet Recruiting
PhaseNot specified
SponsorPfizer
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

First-Line Treatment Patterns
Timeframe: Up to approximately 13 years, 9 months
Real-World Overall Survival (rwOS)
Timeframe: Up to approximately 13 years, 9 months.

Secondary (2)

Treatment patterns following 1L therapy
Real-world effectiveness across lines of therapy

Arms and interventions

Anti-EGFR-Based Therapy Cohort

Patients initiating first-line anti-EGFR therapy combined with standard chemotherapy.

Anti-VEGF-Based Therapy Cohort

Patients initiating first-line anti-VEGF therapy combined with standard chemotherapy.

Drugs: Anti-EGFR-Based Therapy, Anti-VEGF-Based Therapy